




## QUICK FACTS

- USAID supports bilateral programming in 23 countries
- USAID and partners provide technical assistance to 55 countries
- Since 2000, USAID and partners have saved more than 58 million lives globally
- In 2018, \$265 million was allocated to USAID for TB efforts

**USAID leads the U.S. Government’s global tuberculosis (TB) efforts by working with agencies and partners around the world to reach every person with the disease, cure those in need of treatment, and prevent the spread of new infections.**


## TUBERCULOSIS

TB remains the world's deadliest infectious disease. It takes the lives of an estimated 1.5 million people each year - more than HIV and malaria combined. Delayed diagnosis, weak laboratory services and health care, high-risk co-morbidities, and the challenges of drug-resistant TB (DR-TB) cause millions of people across the globe to suffer and die from the disease each year.



### 10M

**new cases of TB**  
*(range, 9.0-11.1 million)*



### 1.5M

**TB deaths**  
*(range, 1.3-1.6 million)*



### 500K

**new drug-resistant TB cases**  
*(range, 420-560K)*



### 330K

**drug-resistant TB cases on treatment**


In September 2018, the United Nations General Assembly High-Level Meeting (UNHLM) on TB set the stage for unprecedented attention and action on TB. This meeting established the ambitious targets of diagnosing and enrolling an additional 40 million people on TB treatment by 2022 (commonly referred to as 40x22), with a focus on countries with the highest TB burden, and enrolling 30 million on TB preventive therapy (commonly referred to as 30x22).

## KEY ACHIEVEMENTS IN USAID TB PRIORITY COUNTRIES

- **44%**  
decrease in TB mortality
- **12.2M**  
people with TB successfully treated
- **330,000**  
DR-TB patients started on treatment
- **89%**  
treatment success rate
- **27%**  
decrease in TB incidence
- **114%**  
increase in TB case notification
- **37M**  
Gene Xpert cartridges procured under concessional pricing

## OUR APPROACH: THE USAID GLOBAL ACCELERATOR TO END TB

For more than 20 years, USAID has been a global leader in the fight against TB. To drive further progress, in September 2018, USAID launched its new TB business model, the Global Accelerator to End TB. The Accelerator is designed to increase investments from the public and private sectors to end the TB epidemic while simultaneously building local commitment and capacity to achieve the targets set forth at the UNHLM in a way that builds self-reliance. It focuses on countries with high burdens of TB where the Agency can align with local communities and partners to deliver performance-based results toward the global targets.



Through the Accelerator, USAID continues to promote prevention strategies, improve patient-centric care, strengthen service delivery, and provide new diagnostics and drugs in the fight against TB. To address the specific challenges of multidrug-resistant tuberculosis (MDR-TB) patients, USAID is expanding the availability of new MDR-TB drugs and regimens that save lives, as well as investing in pivotal clinical trials.

## The Accelerator focuses on three key areas:



### Partnership Statements

USAID Missions have signed partnership statements with Ministries of Health in most USAID TB priority countries. These statements support increased collaboration and coordination to end TB.



### Focused Technical Support

USAID embeds senior-level TB technical advisors in National TB Programs within Ministries of Health to support more sustainable and focused TB programming.



### Locally Generated Solutions

Through the Local Organizations Network, USAID partners directly with local organizations to implement TB diagnosis, treatment, and prevention services.